Loading…
Sotac Pharmaceuticals (SOTAC)₹130.000.00%Pharmaceuticals
In the Mar 2026 quarter (consolidated), Sotac Pharmaceuticals reported sales of ₹60.07 Cr, up 27.6% from Mar 2025, and net profit of ₹3.01 Cr, down 50.0% year on year. For the year to Mar 2026, sales were ₹101 Cr and net profit ₹6.02 Cr.
Company filings, consolidated accounts; latest reported quarter Mar 2026
| Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 38.08 | 52.10 | 52.08 | 53.07 | 47.08 | 37.03 | 60.07 |
| Expenses | 33.90 | 46.85 | 47.81 | 47.87 | 34.87 | 32.88 | 49.84 |
| Operating Profit | 3.99 | 3.98 | 3.98 | 3.99 | 11.95 | 3.98 | 9.97 |
| OPM % | 10.0% | 9.0% | 8.0% | 8.0% | 26.1% | 10.0% | 17.1% |
| Other Income | 0.00 | 0.00 | 0.00 | 1.01 | 0.00 | 4.01 | 0.00 |
| Interest | 1.01 | 1.01 | 1.01 | 1.01 | 2.01 | 2.01 | 2.01 |
| Depreciation | 0.99 | 0.99 | 1.99 | 0.99 | 1.99 | 2.99 | 2.99 |
| Profit before tax | 1.99 | 1.99 | 1.99 | 2.99 | 8.99 | 2.99 | 4.99 |
| Tax % | 34.1% | 45.0% | −33.9% | 30.1% | 13.1% | 23.1% | 31.1% |
| Exceptional items | 0.00 | 0.00 | −0.08 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Profit | 1.01 | 2.01 | 3.01 | 2.01 | 6.02 | 2.01 | 3.01 |
| EPS (Rs) | 1.63 | 1.56 | 2.30 | 1.72 | 5.51 | 2.21 | 2.99 |
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 29.03 | 49.11 | 77.16 | 104 | 97.16 | 101 |
| Expenses | 26.89 | 46.82 | 69.80 | 94.62 | 82.68 | 82.73 |
| Operating Profit | 1.99 | 0.99 | 6.98 | 8.96 | 13.95 | 17.94 |
| OPM % | 7.0% | 3.0% | 10.0% | 8.0% | 14.1% | 18.1% |
| Other Income | 0.00 | 0.00 | 1.01 | 0.00 | 4.01 | 0.00 |
| Interest | 0.00 | 1.01 | 2.01 | 2.01 | 3.01 | 4.01 |
| Depreciation | 0.99 | 2.99 | 1.99 | 2.99 | 3.99 | 4.99 |
| Profit before tax | 0.00 | −1.99 | 3.99 | 3.99 | 10.99 | 8.99 |
| Tax % | 75.1% | 15.1% | 42.1% | 10.1% | 17.1% | 28.1% |
| Exceptional items | 0.00 | 0.00 | 0.32 | −0.04 | 0.33 | 0.00 |
| Net Profit | 0.00 | −2.01 | 2.01 | 4.01 | 9.03 | 6.02 |
| EPS (Rs) | 0.38 | −10.26 | 3.57 | 3.85 | 7.24 | 5.20 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 4.0% |
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 2.01 | 2.01 | 8.01 | 11.01 | 11.01 | 11.01 |
| Reserves | 0.99 | 0.00 | 11.01 | 34.04 | 42.03 | 48.02 |
| Borrowings | 13.03 | 17.03 | 22.05 | 25.04 | 44.06 | 38.07 |
| Other Liabilities | 13.99 | 15.03 | 32.07 | 35.01 | 27.11 | 37.01 |
| Total Liabilities | 30.02 | 35.07 | 74.14 | 105 | 124 | 133 |
| Fixed Assets | 16.01 | 17.04 | 26.05 | 36.07 | 49.09 | 50.04 |
| CWIP | 0.00 | 0.00 | 0.00 | 4.99 | 0.00 | 1.99 |
| Investments | 0.00 | 0.00 | 0.00 | 2.01 | 3.99 | 2.99 |
| Other Assets | 14.01 | 18.03 | 48.09 | 63.03 | 72.13 | 79.09 |
| Inventories | 2.31 | 4.82 | 13.62 | 18.02 | 20.24 | 27.07 |
| Trade receivables | 6.97 | 5.89 | 14.76 | 26.35 | 34.19 | 33.03 |
| Cash & equivalents | 0.42 | 0.26 | 9.65 | 3.41 | 1.55 | 1.17 |
| Total Assets | 30.02 | 35.07 | 74.14 | 105 | 124 | 133 |
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from operating activity | 0.00 | 0.00 | 8.02 | −16.04 | −4.01 | 17.03 |
| Cash from investing activity | −11.99 | −3.01 | −11.99 | −20.01 | −13.99 | −7.01 |
| Cash from financing activity | 10.98 | 2.99 | 12.99 | 28.98 | 15.98 | −9.99 |
| Net cash flow | 0.00 | 0.00 | 9.99 | −5.99 | −1.99 | 0.00 |
| Capex | 9.81 | 3.17 | 9.01 | 12.72 | 17.05 | 6.40 |
| Free cash flow | −10.01 | −3.01 | 0.00 | −33.99 | −16.01 | 9.01 |
| CFO / OP % | 17.1% | 8.1% | 134.1% | −168.0% | −25.9% | 106.1% |
| Mar 2020 | Mar 2021 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor days | 90 | 45 | 71 | 93 | 129 | 120 |
| Inventory days | 41 | 46 | 88 | 84 | 109 | 154 |
| Days payable | 194 | 121 | 162 | 132 | 101 | 154 |
| Cash conversion cycle | −65 | −31 | −4 | 44 | 137 | 119 |
| Working capital days | −79 | −44 | −40 | 47 | 63 | 65 |
| ROCE % | — | −5.0% | — | 10.0% | 15.0% | 13.1% |
For the Mar 2026 quarter, Sotac Pharmaceuticals reported sales of ₹60.07 Cr, up 27.6% year on year and net profit of ₹3.01 Cr, down 50.0% year on year. The operating margin was 17.1%.
Sotac Pharmaceuticals' sales for the year to Mar 2026 were ₹101 Cr.
Net profit for the year to Mar 2026 was ₹6.02 Cr. Earnings per share over the same trailing period were ₹5.20.
Sotac Pharmaceuticals reported borrowings of ₹38.07 Cr at Mar 2026, against cash and equivalents of ₹1.17 Cr.
Cash from operations was ₹17.03 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹9.01 Cr.